Company Overview
Acumen Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of targeted therapies specifically designed for the treatment of Alzheimer's disease. The company is positioned within the Healthcare sector and functions inside the Biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory scrutiny. At a corporate scale, Acumen Pharmaceuticals maintains a market capitalization of $159.31M and employs a workforce of 61 individuals. The combination of a relatively modest market cap and the absence of reported annual revenue indicates that the company remains in an early-stage development phase where value is derived primarily from intellectual property and pipeline potential rather than established commercial sales.
Financial Health
The company reports no revenue (TTM), a net income of $-133,351,000, and an EBITDA of $-138,170,000. The substantial gap between zero revenue and significant negative net income reveals a cost structure dominated by operating expenses such as research and development and general administrative costs, which are typical for clinical-stage biotechnology firms before product launch. Free cash flow stands at $-78,959,504, indicating that the company is currently burning through capital reserves to fund its operations and drug development efforts rather than generating operational cash flow. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that mathematically reflects the absence of revenue and the resulting inability to calculate a positive percentage return on sales. The company holds $126.61M in cash against $30.84M in debt, resulting in a debt-to-equity ratio of 33.09, which suggests a leveraged balance sheet where equity is diluted relative to obligations, though the high cash balance provides a substantial buffer against immediate repayment requirements. The current ratio is 6.02, indicating a highly liquid short-term position where current assets significantly exceed current liabilities, providing ample coverage for short-term obligations. Return on Equity is -85.9% and Return on Assets is -42.2%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a common characteristic of companies in the pre-revenue biotechnology lifecycle where asset bases are built for future commercialization.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is -1.36, implying that the market is pricing the stock based on future expectations of profitability or revenue generation rather than current income performance. The price-to-book ratio stands at 1.71, indicating that the market values the company at a premium of 71% over its net asset book value, suggesting confidence in the intangible value of the drug pipeline despite current losses. The price-to-sales ratio is N/A and the EV/EBITDA is -0.46, suggesting that traditional revenue-based valuation models are not applicable at this stage, and the negative EV/EBITDA further confirms that the company's enterprise value is supported more by its cash position than by current earnings power. The 52-week high is $3.60 and the 52-week low is $0.85, meaning the stock trades within a range of approximately 300% of its lowest point over the past year, reflecting the high volatility inherent in small-cap biotechnology stocks. The beta is 0.21, indicating that the stock's price volatility is significantly lower than that of the broader market, moving at a pace roughly one-fifth as volatile as the market index on average.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, reflecting the fact that the company has not yet generated commercial revenue to establish a growth trajectory or earnings history. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available cash flow is being reinvested directly into research, development, and operational scaling rather than distributed to shareholders. The absence of a dividend payout aligns with the company's lifecycle stage, where capital retention is prioritized to advance the Sabirnetug (ACU193) drug candidate and secure regulatory approvals. The overall growth and income profile is defined by a complete reliance on external capital markets or cash reserves to fund operations, with no current mechanism for generating shareholder income through dividends or revenue expansion.